Overview
Aliquot publishes the narrow regulatory and pharmacokinetic record without extending the label into a benefit claim or personal guidance.
The public record is limited to regulatory status and pharmacokinetic context. The approved product has a specific labeled scope that is not generalized here.
Human pharmacokinetic context
11 hours
FDA prescribing information · subcutaneous injection
Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.
Limitations
- The FDA label applies only to its named approved product and labeled use.
- The label's population pharmacokinetic estimate is not an individual prediction or a dosing interval.
Related calculation tools
Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.
Sources
- Imcivree (setmelanotide) prescribing information Current regulatory status and approximately 11-hour effective elimination half-life.
- Aliquot compound library methodology Editorial scope and withholding rules.